Vein graft failure: current clinical practice and potential for gene therapeutics.
Gene Ther
; 19(6): 630-6, 2012 Jun.
Article
em En
| MEDLINE
| ID: mdl-22456326
ABSTRACT
Autologous saphenous vein is commonly used as a conduit to bypass atherosclerotic lesions in coronary and femoral arteries. Despite the wide use of arterial conduits, which are less susceptible to complications and failure, as alternative conduits, the saphenous vein will continue to be used in coronary artery bypass grafting until acceptable alternative approaches are evaluated. Hence, preservation of vein graft patency is essential for the long-term success. Gene therapy is attractive in this setting as an ex-vivo technology to genetically manipulate the conduit before grafting. The use of safe and efficient vectors for delivery is a necessity as well as a strategy to improve patency in the long term. Here, we review the current clinical practice, the pathogenesis of bypass graft failure and adenovirus-mediated gene therapy strategies designed to improve late vein graft failure by modulation of smooth muscle cells in the vein wall.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Grau de Desobstrução Vascular
/
Falha de Prótese
/
Terapia Genética
/
Ponte de Artéria Coronária
Limite:
Humans
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article